Blockade of the renin-angiotensin system ameliorates apelin production in 3T3-L1 adipocytes

Cardiovascular Drugs and Therapy

Volumn 25, Issue 1, 2011, Pages 3-12

  Hung, Wei Wen ^a,c   Hsieh, Tusty Jiuan ^b   Lin, Tzu ^b   Chou, Pong Chun ^a   Hsiao, Pi Jung ^a   Lin, Kun Der ^a   Shin, Shyi Jang ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Adipocyte; Adipokine; Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Angiotensinogen

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; APELIN; BETA ACTIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE 1; FAT DROPLET; LOSARTAN; MESSENGER RNA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PERINDOPRIL; REACTIVE OXYGEN METABOLITE; RENIN; RESISTIN; RETINOL BINDING PROTEIN 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANGIOTENSIN CONVERTING ENZYME 1 GENE; ANGIOTENSIN TYPE 1 RECEPTOR GENE; ANGIOTENSIN TYPE 2 RECEPTOR GENE; ANGIOTENSINOGEN GENE; ANIMAL CELL; APELIN GENE; ARTICLE; BETA ACTIN GENE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; LIPID STORAGE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RBP4 GENE; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN GENE; RESISTIN GENE; RNA SEQUENCE; SEQUENCE ANALYSIS; TUMOR NECROSIS FACTOR ALPHA GENE; UPREGULATION; VISFATIN GENE;

3T3-L1 CELLS; ADIPOCYTES; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSINOGEN; ANIMALS; CAPTOPRIL; CELLS, CULTURED; IMIDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPID METABOLISM; LOSARTAN; MICE; PERINDOPRIL; PYRIDINES; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER;

EID: 79959952637     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-010-6274-4     Document Type: Article

References (49)

1. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352:1138-45. (Pubitemid 40365358)
2. Sorensen TI, Virtue S, Vidal-Puig A. Obesity as a clinical and public health problem: is there a need for a new definition based on lipotoxicity effects? Biochim Biophys Acta. 2010;1801:400-4.
3. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006;444:847-53. (Pubitemid 46024991)
4. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764-71. (Pubitemid 40396885)
5. Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab. 2008;8:437-45.
6. Wei L, Hou X, Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept. 2005;132:27-32. (Pubitemid 41607499)
7. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35:807-25. (Pubitemid 36379323)
8. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev. 2003;4:43-55. (Pubitemid 36356409)
9. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264:224-36.
10. Aubert J, Darimont C, Safonova I, Ailhaud G, Negrel R. Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells. Biochem J. 1997;328:701-6. (Pubitemid 27515619)
11. Mogi M, Iwai M, Horiuchi M. Emerging concept of adipogenesis regulation by the renin-angiotensin system. Hypertension. 2006;48:1020-2. (Pubitemid 44772700)
12. Crandall DL, Herzlinger HE, Saunders BD, Armellino DC, Kral JG. Distribution of angiotensin II receptors in rat and human adipocytes. J Lipid Res. 1994;35:1378-85. (Pubitemid 24251032)
13. Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology. 1997;138:1512-9. (Pubitemid 27137101)
14. Yvan-Charvet L, Massiera F, Lamande N, et al. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinology. 2009;150:1421-8.
15. Kouyama R, Suganami T, Nishida J, et al. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology. 2005;146:3481-9. (Pubitemid 41065022)
16. Kurata A, Nishizawa H, Kihara S, et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006;70:1717-24. (Pubitemid 44684802)
17. Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens. 2008;21:206-12. (Pubitemid 351231578)
18. Putt FA. Manual of histopathological staining methods. New York: Wiley; 1972.
19. Baehner RL, Boxer LA, Davis J. The biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polymorphonuclear leukocytes. Blood. 1976;48:309-13.
20. Campbell DJ, Habener JF. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology. 1987;121:1616-26. (Pubitemid 18012763)
21. Saye J, Lynch KR, Peach MJ. Changes in angiotensinogen messenger RNA in differentiating 3T3-F442A adipocytes. Hypertension. 1990;15:867-71. (Pubitemid 20189471)
22. Schling P, Mallow H, Trindl A, Loffler G. Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord. 1999;23:336-41. (Pubitemid 29182390)
23. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270-7. (Pubitemid 30413663)
24. Schling P, Loffler G. Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensin system in human preadipocytes. Horm Metab Res. 2001;33:189-95. (Pubitemid 32452793)
25. Mallow H, Trindl A, Loffler G. Production of angiotensin II receptors type one (AT1) and type two (AT2) during the differentiation of 3T3-L1 preadipocytes. Horm Metab Res. 2000;32:500-3. (Pubitemid 32176077)
26. Yvan-Charvet L, Even P, Bloch-Faure M, et al. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes. 2005;54:991-9. (Pubitemid 40446313)
27. Fowler JD, Johnson ND, Haroldson TA, Brintnall JA, Herrera JE, Katz SA, et al. Regulated renin release from 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab. 2009;296:E1383-91.
28. Saye JA, Ragsdale NV, Carey RM, Peach MJ. Localization of angiotensin peptide-forming enzymes of 3T3-F442A adipocytes. Am J Physiol. 1993;264:C1570-6. (Pubitemid 23198527)
29. Muñoz MC, Giani JF, Dominici FP, Turyn D, Toblli JE. Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens. 2009;27:2409-20.
30. Mori Y, Itoh Y, Tajima N. Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens. 2007;20:431-6. (Pubitemid 46441748)
31. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF. The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq Bras Cardiol. 2008;90:343-9.
32. Sunter D, Hewson AK, Dickson SL. Intracerebroventricular injection of apelin-13 reduces food intake in the rat. Neurosci Lett. 2003;353:1-4. (Pubitemid 37464605)
33. Lee DK, George SR, O'Dowd BF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci. 2006;27:190-4.
34. Principe A, Melgar-Lesmes P, Fernandez-Varo G, et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology. 2008;48:1193-201.
35. Yue P, Jin H, Aillaud-Manzanera M, et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab. 2010;298:E59-67.
36. Higuchi K, Masaki T, Gotoh K, et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology. 2007;148:2690-7. (Pubitemid 46984786)
37. Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118:3343-54.
38. Heinonen MV, Purhonen AK, Miettinen P, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept. 2005;130:7-13. (Pubitemid 40966016)
39. Castan-Laurell I, Vitkova M, Daviaud D, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol. 2008;158:905-10. (Pubitemid 351837380)
40. Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006;114:544-8. (Pubitemid 46087259)
41. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008;116:289-92. (Pubitemid 351798738)
42. Brody R, Peleg E, Grossman E, Sharabi Y. Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs. Am J Hypertens. 2009;22:1126-9.
43. Kiess W, Petzold S, Topfer M, et al. Adipocytes and adipose tissue. Best Pract Res Clin Endocrinol Metab. 2008;22:135-53. (Pubitemid 351222159)
44. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010;2010:535918. Epub 2010 Aug 5.
45. Falcão-Pires I, Gonc̃alves N, Henriques-Coelho T, Moreira-Gonçalves D, Roncon-Albuquerque Jr R, Leite-Moreira AF. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2009;296:H2007-14.
46. Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA, et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol. 2009;296:H1329-35.
47. Wang B, Jenkins JR, Trayhurn P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab. 2005;288:E731-40. (Pubitemid 40397208)
48. Kang YS, Song HK, Lee MH, Ko GJ, Cha DR. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes Res Clin Pract. 2010;89:141-9.
49. Lee MH, Song HK, Ko GJ, et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int. 2008;74:890-900.